title: Novel Multivalent Wound-Healing Ointment Provides Bioburden Control and Moisture Management: A Retrospective Registry Data Analysis.
abstract: OBJECTIVE
  The purpose of this retrospective registry data analysis was to explore the effectiveness of a novel multivalent topical ointment (Terrasil Infection Control Wound Care Ointment; Aspiera Medical, Woonsocket, Rhode Island), containing a patented mineral complex and 0.2% benzethonium chloride in the treatment of nonhealing acute and chronic wounds.
  
  
  METHODS
  Aspiera Medical designed a registry to capture physician experiences and treatment results with Terrasil Infection Control Wound Care Ointment. Physicians were asked to enter deidentified patient data into an online registry.
  
  
  METHODS
  Wound clinics in the United States were asked to participate in the registry.
  
  
  METHODS
  Physicians at 4 wound clinics treated 30 patients (26 of whom completed the treatment) with various chronic wounds that had persisted for an average of 6 months and entered treatment data into the registry.
  
  
  METHODS
  Patients applied the ointment according to physician orders. Concurrent treatments used by patients included offloading, compression wraps, and dressings, such as collagen and calcium alginate. Patients were treated until complete wound closure or lost to follow-up.
  
  
  METHODS
  Physicians calculated each patient's percentage wound reduction at each visit.
  
  
  RESULTS
  Thirty patients were entered into the registry. Pretreatment and posttreatment measurements were available for 26 of them. Patients achieved an average surface area reduction of 84% in a mean of 23 days' treatment.
  
  
  CONCLUSIONS
  The antimicrobial and moisturizing ointment studied appears to be effective in promoting wound closure in a variety of acute and chronic wounds. Wounds studied included diabetic foot ulcers, venous leg ulcers, venous stasis ulcers, surgical infections, burns, and insect bites. The results of this registry data analysis will be used to inform planned clinical trials.
authors.affiliation: Thomas Serena, MD, FACS, is Chief Executive Officer and Medical Director, SerenaGroup, Cambridge, Massachusetts. Heather Connell, BS, CCRP, is Clinical Research Manager, SerenaGroup, Pittsburgh, Pennsylvania. Sharon McConnell, MS, CCRP, is Director of Research, SerenaGroup, Pittsburgh, Pennsylvania. Keyur Patel, DO, and Bryan Doner, DO, are Co-Medical Directors; and Matthew Sabo, DPM, FACFAS, is Associate Director of Research/Staff Physician, The Wound Healing and Hyperbaric Center, ACMH, Kittanning, Pennsylvania. Michael Miller, DO, is Chief Executive Officer and Medical Director, Miller Care Group, Indianapolis, Indiana. Laura Serena, MEd, LPN, is Co-Safety Director, The Wound Healing and Hyperbaric Center, ACMH, Kittanning, Pennsylvania; and is Program Manager, SerenaGroup, Pittsburgh, Pennsylvania. Lam T. Le, MD, is Medical Director, St John Wound Center, Tulsa, Oklahoma. David Goldsmith, BS, is Director, Aspiera Medical, Woonsocket, Rhode Island. Jane Chung, BS, is a Medical Student, Dean's Summer Research Program-Georgia Regents University/University of Georgia Medical Partnership, Athens, Georgia.
authors.forename: Thomas
authors.initials: T
authors.lastname: Serena
authors.forename: Heather
authors.initials: H
authors.lastname: Connell
authors.forename: Sharon
authors.initials: S
authors.lastname: McConnell
authors.forename: Keyur
authors.initials: K
authors.lastname: Patel
authors.forename: Bryan
authors.initials: B
authors.lastname: Doner
authors.forename: Matthew
authors.initials: M
authors.lastname: Sabo
authors.forename: Michael
authors.initials: M
authors.lastname: Miller
authors.forename: Laura
authors.initials: L
authors.lastname: Serena
authors.forename: Lam T
authors.initials: LT
authors.lastname: Le
authors.forename: David
authors.initials: D
authors.lastname: Goldsmith
authors.forename: Jane
authors.initials: J
authors.lastname: Chung
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D001558:Benzethonium / Q000627:therapeutic use*; D002908:Chronic Disease; D017719:Diabetic Foot / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007871:Leg Ulcer / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D009779:Occlusive Dressings; D009824:Ointments / Q000627:therapeutic use; D011379:Prognosis; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014647:Varicose Ulcer / Q000175:diagnosis / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology; D014947:Wounds and Injuries / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D009824:Ointments; D001558:Benzethonium